Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Prasugrel Overcomes Cancer Hurdle, Receives Favorable Panel Recommendation

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Cardio-Renal Advisory Committee says cancer risk possibly associated with the platelet inhibitor does not warrant strong warning in label or use restrictions.

You may also be interested in...



Effient Review Delayed More By Management Issues Than Clinical Disputes

Review management issues, more than unresolved clinical debates, are what produced FDA's lengthy and overdue review of Lilly/Daiichi Sankyo's antiplatelet agent Effient (prasugrel), FDA review documents indicate

Effient Review Delayed More By Management Issues Than Clinical Disputes

Review management issues, more than unresolved clinical debates, are what produced FDA's lengthy and overdue review of Lilly/Daiichi Sankyo's antiplatelet agent Effient (prasugrel), FDA review documents indicate

Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics

FDA cleared Lilly/Daiichi Sankyo's oral platelet inhibitor Effient (prasugrel) at both 5 mg and 10 mg doses on July 10, with a carefully constructed label that reflects the level of regulatory consideration - and negotiation - that went into the approval

Related Content

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel